The HMGB1 Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HGC-27 human gastric carcinoma cell line, engineered to disrupt the HMGB1 gene. This polyclonal population provides a loss-of-function model for studying the roles of HMGB1 in gastric cancer biology and inflammation-associated signaling. The polyclonal format captures the heterogeneity of CRISPR/Cas9-mediated editing events across the cell pool, enabling robust functional studies without clonal selection artifacts.
The parental HGC-27 cell line originates from the lymph node metastasis of a human gastric adenocarcinoma and is widely employed as an in vitro model of metastatic gastric cancer. These epithelial cells retain key characteristics of advanced gastric carcinoma, including aggressive migratory and proliferative capacity, making them a relevant system for investigating molecular mechanisms driving tumor progression and metastasis. The knockout cells thus allow direct interrogation of HMGB1 function in a clinically pertinent metastatic background.
HMGB1 is a multifunctional DNA-binding protein that stabilizes nucleosomes and modulates transcription intracellularly, while extracellularly it acts as a damage-associated molecular pattern (DAMP) to promote inflammation and cell migration. HMGB1 is secreted in response to various stimuli, including LPS, TNF-??, IL-1??, hypoxia/HIF-1??, and oxidative stress. Upon release, HMGB1 engages receptors such as TLR4 and RAGE, together with coreceptors TIRAP and MD-2, to activate downstream signaling cascades. Key pathways include TLR4/NF-??B and RAGE-mediated MAPK/ERK signaling. Representative pathway components comprise MyD88, IRAK, TRAF6, NF-??B, ERK1/2, p38 MAPK, and JNK. These pathways lead to the transcriptional upregulation of pro-inflammatory mediators and angiogenic factors such as IL-6, IL-8, and VEGF. In knockout cells, depletion of intracellular HMGB1 alters DNA binding and transcription, while loss of secreted HMGB1 attenuates autocrine and paracrine signaling through TLR4 and RAGE, thereby reducing NF-??B and MAPK activation and impairing inflammation, migration, and proliferation.
In the HGC-27 gastric cancer context, HMGB1 knockout provides a powerful tool to dissect the contribution of HMGB1-mediated DAMP signaling to tumor cell-autonomous and microenvironmental processes. The attenuation of TLR4/NF-??B and RAGE/MAPK/ERK pathways is expected to diminish the production of cytokines and growth factors that support gastric cancer progression. This model enables researchers to evaluate how loss of HMGB1 influences metastatic behaviors, such as epithelial?Cmesenchymal transition and invadopodia formation, and to explore its role in therapy resistance mechanisms often linked to chronic inflammation.
This knockout cell population is well-suited for a range of downstream applications including Western blotting and RT-qPCR to confirm target-gene disruption and downstream effector expression, Transwell migration and invasion assays to assess metastatic potential, NF-??B luciferase reporter assays to quantify pathway activity, ELISA for cytokine secretion (e.g., IL-6), flow cytometry for apoptosis and cell cycle analysis, RNA-seq for global transcriptomic profiling, and co-immunoprecipitation to identify interacting partners. By enabling comprehensive functional and mechanistic studies, the HMGB1 Knockout HGC-27 Polyclonal Cells support cancer drug discovery, target validation, and the screening of HMGB1 inhibitors in gastric adenocarcinoma. For further details, please contact Ascent Research.
